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Abstract 
Estrogen are potent mitogenic stimuli that share important properties in the control of cellular proliferation. 
Increased expression and/or activity of estrogen reseptor (ER) result in aberrant activation of downstream 
signaling pathways including cAMP/PKA, MAPK/ERK and PI3K/AKT. The importance of estrogen and as a 
signaling axis in cancer development, progression and metastasis is highlighted by its effects on cancer cells, 
notably proliferation.  But, all mechanism of this proliferation action ER and Ki67 not complete clear yet. The 
study aims to explore the coupling between the signaling cascades of estrogen receptors  to celular proliferation 
(Ki67). This research used an exploration analitik with  cross sectional design, 59 specimen pathologi were 
explore with Immunohistochemia (IHC) examine to asses expression of Estrogen reseptor and Ki67 in invasif 
ductal breast cancer. To asses corelation beetwen ER and  Ki67 with Chi-Square Test. Result found that the IHC 
examation show that propotion   ER. : 35/ 55 (63 %), Ki67 :32/55 ( 58 %) in invasive ductal breast cancer. 
Correlated beetwen ER  and  Ki67 expression  no signiﬁcant   p>0.05 in invasif ductal breast cancer. In 
conclution, ER does not play a signiﬁcant role in celluler proliferation in Invasive breast cancer. 
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1. Introduction 
The number of new cases in the USA in 2013 an estimated 232 340 newly diagnosed invasive breast cancer [1, 
2]. The incidence of breast cancer in Asia each year 3-4% [3]. Obtained 20-30% of breast cancer have metastatic 
or locally advanced disease, and another 30% have recurrent or metastatic [4]. The role of estrogen in breast 
cancer carcinogenesis focused on the production of estrogen in breast tissue [5]. The high plasma estradiol 
levels significantly associated with breast cancer risk in postmenopausal especially tumor ER / PR +, while ER 
+ / PR- intermidiet, ER- / PR- estradiol no significant effect [6]. 
Tumor cell proliferation due to the involvement of estrogen / ER in mammary gland development and breast 
cancer is focused on the action of estrogen on the control of cell cycle G1 phase development / S. Activation of 
cyclin D1 gene expression is an essential feature of these hormones work [7]. Cyclin D1 is a key regulator of 
cell cycle proteins that exhibit oncogenic activity in a variety of malignancies. Cyclin D1 mRNA and protein 
were expressed in about 50% of primary breast carcinoma [8]. The existence of fast track / nongenomic 
estradiol-regulated protein kinase C (PKC) and the path of signal transduction extracellular signal-regulated 
kinase (ERK), and cross-talk, and who played in the synthesis of DNA and gene transcription of cyclin D1 [7], 
as a result of the activation of ER changes in transcriptional activity and gene expression profile of the target. A 
number of genes, including cathepsin D, cyclin D1, c-Myc and regulated by the progesterone receptor ER-alpha 
[9]. Tumor cell proliferation due to activation of estrogen / ER of the cell cycle, can be identified by the core 
antigen Ki67. Ki-67 is a core protein associated with cellular proliferation, Ki-67 is a nuclear antigen identified 
in 1983 where the Ki-67 appears in the nucleus of cells in all phases of the cell cycle when mitosis S, G1, G2, 
and M, except on the GO [10]. 
2. Materials and Methods  
2.1 Research Design  
This study is a cross-sectional study Ekxplorasi with analytic methods. 
1. Laboratory procedure 
a. The biopsy section of breast cancer patient were processed into formalin-fixed paraffin-embedded (FFPE) 
block, then Examined with immunohistochemistry stain of Estrogen Receptor (ER) and Ki67 as a target sample. 
The answer sheet analyze to take the datas. The FFPE blocks were selected to the make sure the blocks were 
standarized and the tumor was representative. Every block was cutted by microtome with 4 mm in size and 
placed in glass object. The immunohistochemistry stain using standard technique. From every block, one slide 
was stained with haematoxyln-eosin for histopathology, one slide for ER and one slide for Ki67. The stained 
slides were evaluated microscopically to Determine cancer types, and the immunohistochemistry expression of 
ER and Ki67. 
b. Immunohistochemistry stain methods: using avidin-biotin-peroxidase complex  
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methods. Before the staining process, every slides must deparaffinized with xylene (twice for 10 minutes each), 
rehydrated through graded alcohol (5 minutes with alcohol 100%, 5 minutes with alcohol 95%, and 1 minutes 
with alcohol 70%), and washed in phosphate-buffered solution (PBS) liquid for 5 minutes. The antigen retrieval 
procedure then applied. Place the slides on the rack and rinsed with citrate buffer (10 mM, pH 6.0) using a 
microwave in a high power level for 5 minutes and a low power level in 5 minutes. After chilled and washed 
with PBS, block the non-specific binding site activity using Normal Horse Serum for 20 minutes, then incubate 
overnight using primary mouse monoclonal antibody for ER (DACO), Ki67 (Daco). After washed with PBS, the 
section incubated with a secondary immunoglobuline antibody / Biotynylated BIOCARE for 30 minutes, 
washed with PBS, and reincubated with Streptavidine (BIOCARE) for 60 minutes, incubated with chromogen 
Diaminobenzidine (DAB) in Tris-HCl pH 7.6 for 10 minutes , and then counterstained with weak Lili-Mayer's 
hematoxylin, dehydrated with graded alcohol, and cleared using xylol. Lastly, the slides covered with mounting 
medium and de glass. Immunohistochemistry slides were evaluated microscopically by two pathologist and the 
researcher to the make accurate conclusion. 
C. Immunohistochemistry results intrepretation 
ER, Ki67 expression are proteins accumulation in the cell membrane and cell cytoplasm, detected using 
immunohistochemistry methods roomates Expressed using light microscope will positively stained brown in 
color on antigen location. Reviews these expression were counted using a scoring system based on color 
intensity and proportion of colored epithelial cells 
2.2 Data Processing and Analysis 
The collected data are grouped by destination and type of data is then determined appropriate statistical 
methods, namely: 
1. The bivariate analysis used X2 test for unpaired samples for which data are nominal dichotomous scale. The 
test is to assess the relationship between the nominal scale variables unpaired two groups. In this case 
comparing the expression of ER and Ki67 expression invasive ductal breast carcinoma. 
3. Results 
3.1 Characteristics of the sample 
ER Immunohistochemical examination results showed 35 samples (63.6%) expressed positive and 20 samples 
(36.4%) expressed a negative. While the results of Ki67 obtained 32 samples (58.2%) expressed positive, and 23 
samples 41.8% expressed a negative. 
3.2 Analysis of the relationship between the Expression of ER with Ki67 expression 
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Table 1: Characteristics of the study sample (n = 55) invasive ductal breast cancer 
 
 
 
 
 
Expalnation  n= number;  ER= Estrogen Reseptor ; Reseptor, Ki67= antigen cancer Ki67 
Table 2: Analysis of the relationship between the expression of ER with the expression of Ki67 
ER expression  
Ki67 expression  
Number  x2 (p value) 
Positive  (%) Negative (%) 
Positive 20(57,1) 15(42,9) 35(100) 0, 043 
(0,836) Negative 12(60) 8(40) 20(100) 
Total 32(58,2) 23(41,8) 55 (100) 
Table 2 shows the positive expression of ER in breast invasive ductal carcinoma as many as 35 samples 
(63.6%). While expression of Ki67 positive in 32 samples in invasive ductal carcinoma of the breast. From the 
analysis using Chi-Square test, the value p = 0836 which means there is no correlation between the expression 
of ER with significant Ki67 in invasive ductal carcinoma of the breast. However, when viewed from the 
distribution of proportions, expression of ER positive for Ki67 expression was found that invasive ductal breast 
carcinoma expressing the positive ER tends expressing Ki67 positive (57.1%) is greater than the expression of 
Ki67 negative (42.9%). On the other side of invasive ductal breast carcinoma expression of ER negative, 
obtained expression of Ki67 positive proportion of 60%. 
4. Discussion  
ER against Ki67 in invasive ductal breast carcinoma 
This study shows that the expression of ER positive invasive ductal carcinoma of the breast 35 (63.6%) of 55 
samples of invasive ductal carcinoma of the breast. Other studies such as research Shapochka and his colleagues 
reported the expression of ER + breast cancer 76%, research Mylonas and his colleagues ER expression 45.9% 
[11]. Research Nishimura and his colleagues showed 63% positive ER expression in primary tumors [12]. The 
Characteristics  Explanation     n % 
Age  <55 years    35 63.6 
≥55 years    20 36,4 
Histopalogi degree  Good Diferensiasi  8 14,5 
Middle Diferensiasi  31 56.4 
Bad Diferensiasi  16 29,1 
ER Expression   Positive 35 63.6 
Negative 20 36.4 
Ki67 Expression Positive  32 58.2 
Negative  23 41,8 
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high plasma estradiol levels significantly associated with breast cancer risk in postmenopausal especially tumor 
ER / PR +, while ER + / PR- intermediate, and ER + / PR- estradiol no significant effect [6]. Overexpression of 
ER alpha and ER beta is very significantly higher in women with prior diagnosis of invasive ER + breast cancer 
[13]. Research estradiol levels in plasma estradiol level in the multiethnic showed no strong relationship to the 
risk of breast cancer, but the risk is different in ethnicity [14]. The high level of estradiol is associated with 
increased risk of ER-positive breast cancer [13]. The high serum estradiol levels in postmenopausal also 
influence the prognosis of ER- breast cancer preoperatively especially, run the risk of metastasis than ER + 
(fifteenth). This research obtains Ki67 expression was positive 32 (58.2%) of 55 samples of invasive ductal 
carcinoma of the breast. Other studies such as research shapochka and his colleagues Reported a 47% Ki67 
expression [16] while research Mylonas and his colleagues Ki67 36% [11]. Research Nishimura and his 
colleagues showed expression of Ki67 expression + 12.4% in primary tumors [12]. This study found that the 
proportion of Ki67 expression (+) of 20 (57.1%) of 35 samples in invasive ductal carcinoma of the breast that 
express ER (+). From the analysis we found no significant relationship between the expression of ER with Ki67 
expression p = 0836. From the results of the analysis showed that the expression of Ki67 (+) tergatung not fully 
Expression of ER (+), but by multiple factors other signaling pathways contributing to the expression of Ki67 
(+). While research Pietilainen and his colleagues showed no significant relationship [17,18]. In this study, there 
is a negative ER expression showed greater expression of Ki67 positive (60.4%) in invasive ductal carcinoma of 
the breast so that the implications in the clinic presenting a poor prognosis. This study shows that the expression 
of ER positive invasive ductal carcinoma of the breast 35 (63.6%) and the expression of Ki67 positive 32 
(57.1%). Penilitian Shapochka and his colleagues expression of ER + breast cancer 76%, 47% Ki67 expression 
(16) while research Mylonas and his colleagues expression of ER and Ki67 45.9% 36% (11). Research 
Nishimura and his colleagues showed positive expression of ER 63%, and the expression of Ki67 + 12.4% in 
primary tumors [12]. In this study it was found that the percentage of positive Ki67 expression was greater in 
the number of ER negative (60%) compared to ER positive (57.1%). The analysis showed there was no 
significant relationship between the expression of ER with Ki67 expression p = 0836. while research Pietilainen 
and his colleagues showed no significant relationship [17,18]. There is a tendency that showed greater 
expression of Ki67 positive (60.4%) in breast carcinoma expression of ER negative invasive ductal allegedly 
caused by cross-talk ER Receptor tyrosine kinases (Estrogen independent) so that the implications of the clinic 
presented a poor prognosis. Ki67 has been regarded as a prognostic sign of invasive ductal carcinoma of the 
breast [17-19], and as a factor predictor of response to chemotherapy [20, 21]. Rate Ki67 expression was already 
a recommendation on breast cancer can be as prognosis, prediction of the patients who received standard 
therapy, even as biomarkers before, during and after neoadjuvant treatment, especially neoadjuvant endocrine 
therapy [25]. With ER + breast cancer, can be a biomarker Ki67 not been accepted as standard, but can Ki67 
free prognostic factor for disease-free survival. [26]. Likewise, the response can Ki67 as a prognostic factor in 
patients with ER + breast cancer who had received neoadjuvant tamosifen short term and can be a predictor of 
recurrence (DFS) [27]. Research Shapochka and his colleagues showed that Ki67 expression based on the 
subtype of breast cancer is highest in Her-2 type, basal like. [16]. Reported that the decreased expression of ER 
and Ki67 expression significantly increase the risk of recurrence, while the Expression of ER positive and Her-2 
showed no significant change in recurrence rates [12]. 
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5. Conclusion 
This study showed that ER does not play a significant role in cellular proliferation in invasive ductal carcinoma 
of the breast. 
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